Vimentin Antibody, anti-human, PE, REAfinity™ | Miltenyi Biotec 130-106-296 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Miltenyi Biotec

product type :

antibody

product name :

Vimentin Antibody, anti-human, PE, REAfinity™

catalog :

130-106-296

quantity :

100 tests in 1 mL

price :

278,00 USD

clonality :

monoclonal

host :

human

conjugate :

clone name :

REA409

reactivity :

human

application :

immunohistochemistry, immunocytochemistry

citations: 1

Reference
Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci. 2011;68:3033-46 pubmed publisher

product information

Catalog Number :

130-106-296

Product Name :

Vimentin Antibody, anti-human, PE, REAfinity™

Product Type :

Antibodies

Host Species :

cell line

Clonality :

monoclonal

Conjugation :

Antigen Modification :

Vimentin

Clone Name :

REA409

Isotype :

recombinant human IgG1

Light Chain :

kappa light chain

Size :

100 tests in 1 mL

US List Price :

278,00 USD

Product Description :

Clone REA409 recognizes the human vimentin antigen, a 57 kDa molecule which is one of the most widely expressed and highly conserved proteins of the type III intermediate filament (IF) protein family. Vimentin is expressed in a wide range of cell types, including pancreatic precursor cells, sertoli cells, neuronal precursor cells, trophoblastic giant cells, fibroblasts, endothelial cells lining blood vessels, renal tubular cells, macrophages, neutrophils, mesangial cells, leukocytes, and renal stromal cells. Increased vimentin expression has been reported in various epithelial cancers including prostate cancer, gastrointestinal tumors, CNS tumors, breast cancer, malignant melanoma, lung cancer, and other types of cancers. Vimentin's over-expression in cancer correlates well with increased tumor growth, invasion, and poor prognosis. Vimentin has gained much importance as a canonical marker of epithelial-mesenchymal transition (EMT), a cellular re-programming process in which the epithelial cells acquire a mesenchymal phenotype that renders the cells to dramatically alter their shape and exhibit increased motility. This EMT is characterized by the expression of vimentin IFs in epithelial cells, which normally express only keratin IFs. Accordingly, during the reverse process of EMT, known as mesenchymal-epithelial transition (MET), the cells start acquiring epithelial phenotype and show a decreased vimentin expression with lower motility rates. Additional information: Clone REA409 displays negligible binding to Fc receptors.

ALTnames :

VIM, CTRCT30, HEL113

Specificity :

human

Concentration :

1:11

Uses :

For research use only

Application Summary :

Intracellular flow cytometry, Multiparameter imaging cell screen, Immunofluorescence, Immunohistochemistry, Immunocytochemistry

Storage :

Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.